Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma
Jacqueline Plesset, Meredith L. Stone, John C. McVey, Heather Coho, Kelly Markowitz, Kayjana Coho, Jesse Lee, Anna S. Thickens, Devora Delman, Gregory L. Beatty
Jacqueline Plesset, Meredith L. Stone, John C. McVey, Heather Coho, Kelly Markowitz, Kayjana Coho, Jesse Lee, Anna S. Thickens, Devora Delman, Gregory L. Beatty
View: Text | PDF
Research Article Immunology Inflammation Oncology

TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDAC) shows profound resistance to immunotherapy due to its immunosuppressive tumor microenvironment. Here, we studied the relationship between T cell infiltration and innate immune signaling in PDAC, identifying TLR2 as a key regulator of T cell exclusion. TLR2 expression correlated with T cell infiltration in both human and mouse PDAC tumors. Using genetic KO models and adoptive T cell transfer experiments, we found that TLR2 expression in both T cells and non–T cells contributes to T cell exclusion in PDAC. Notably, successful infiltration of adoptively transferred tumor-specific T cells required TLR2 deletion in both the transferred cells and the recipient host. The therapeutic implications of these findings are demonstrated through both genetic deletion and pharmacological inhibition of TLR2 using AAV-mediated and antibody-based approaches in murine models, resulting in decreased tumor growth and extended survival. Collectively, these findings identify TLR2 as a key modulator of T cell trafficking and immune suppression within the PDAC microenvironment, suggesting its potential as a therapeutic target for improving treatment outcomes.

Authors

Jacqueline Plesset, Meredith L. Stone, John C. McVey, Heather Coho, Kelly Markowitz, Kayjana Coho, Jesse Lee, Anna S. Thickens, Devora Delman, Gregory L. Beatty

×

Figure 3

TLR2 expression in both T cells and host cells regulates T cell infiltration in PDAC.

Options: View larger image (or click on image) Download as PowerPoint
TLR2 expression in both T cells and host cells regulates T cell infiltra...
(A) Study design of B–D. T celllo (PDA.69) cells where s.c. implanted into Tlr2+/+ and Tlr2–/– mice on day –10. On Day –1, mice received Cy (120 mg/kg dose, i.p.) and then Tlr2+/+ or Tlr2–/– CART cells on day 0 with necropsy 10 days later. (B) Representative images of tumors stained for GFP (teal), CD3 (brown), and CK19 (yellow). Scale bar: 60 μm. (C) Analysis of CART cell densities (GFP stained) from B (n = 7–8/group, Mann-Whitney U test performed). (D) Analysis of CART cell percentages in the tumors via flow cytometry (n = 7–8/group, Mann-Whitney U test performed). In C and D, black represents Tlr2+/+ mice while purple represent Tlr2–/– mice. Open circles represent Tlr2–/– CAR T cells, while closed circles represent Tlr2+/+ CAR T cells.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts